Wild-type (senile) amyloidosis laboratory findings: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Wild-type (senile) amyloidosis}} | {{Wild-type (senile) amyloidosis}} | ||
{{CMG}} | {{CMG}}{{shyam}}{{AE}}{{Sab}}{{SHH}} | ||
==Overview== | ==Overview== | ||
Wild-type (senile) amyloidosis is a [[diagnosis]] of exclusion. [[Laboratory]] tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. The absence of AL amyloid provides a strong clue towards the provisional [[diagnosis]] of wild-type (senile) amyloidosis. [[Cardiac biomarkers]] are the most important predictors of outcome in amyloidosis. | |||
==Laboratory Findings== | ==Laboratory Findings== | ||
* Wild-type (senile) amyloidosis is a diagnosis of exclusion. | * Wild-type (senile) amyloidosis is a [[diagnosis]] of exclusion. | ||
* Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. | *[[Laboratory]] tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. | ||
* The absence of AL amyloid provides a strong clue towards the diagnosis of wild-type (senile) amyloidosis. | * The absence of AL amyloid provides a strong clue towards the provisional [[diagnosis]] of wild-type (senile) amyloidosis. | ||
==='''Cardiac'''=== | ==='''Cardiac'''=== | ||
Latest revision as of 21:58, 17 December 2019
|
Wild-type (senile) amyloidosis Microchapters |
|
Differentiating Wild-type (senile) amyloidosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Wild-type (senile) amyloidosis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Wild-type (senile) amyloidosis laboratory findings |
|
Wild-type (senile) amyloidosis laboratory findings in the news |
|
Risk calculators and risk factors for Wild-type (senile) amyloidosis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Shyam Patel [2]Associate Editor(s)-in-Chief: Sabawoon Mirwais, M.B.B.S, M.D.[3]Shaghayegh Habibi, M.D.[4]
Overview
Wild-type (senile) amyloidosis is a diagnosis of exclusion. Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition. The absence of AL amyloid provides a strong clue towards the provisional diagnosis of wild-type (senile) amyloidosis. Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
Laboratory Findings
- Wild-type (senile) amyloidosis is a diagnosis of exclusion.
- Laboratory tests are conducted to evaluate for the presence or absence AL amyloid protein deposition.
- The absence of AL amyloid provides a strong clue towards the provisional diagnosis of wild-type (senile) amyloidosis.
Cardiac
- Cardiac biomarkers are the most important predictors of outcome in amyloidosis.
- They provide a quantitative assessment for cardiac damage and wall strain.[1]
- The biomarkers include:
- Troponin I or Troponin T
- BNP and NT-proBNP
Nervous
- In the case of CNS involvement (carpal tunnel syndrome), the following tests should be ordered for confirmation of the presenting symptoms:
References
- ↑ Merlini G, Seldin DC, Gertz MA (May 2011). "Amyloidosis: pathogenesis and new therapeutic options". J. Clin. Oncol. 29 (14): 1924–33. doi:10.1200/JCO.2010.32.2271. PMC 3138545. PMID 21483018.